Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASER in Acute Flare of Pediatric Crohn's Disease
NCT00495521Phase 2Terminated
- Sponsor
- Jacobus Pharmaceutical Company Inc.
- Start
- Jun 2007
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing Active (PASER) with Placebo (2 arms). Primary endpoint: Reduction in Modified Crohn's Disease Activity Index at 4 weeks. Started Jun 2007; status: terminated.
02
Drugs
4-aminosalicylic acid
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00495521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00495521.